Dataset Information


Efficacy of Ageratum conyzoides extracts against Giardia duodenalis trophozoites: an experimental study.

ABSTRACT: BACKGROUND:Giardia duodenalis causes giardiasis in humans, particularly in developing countries. Despite the availability of treatments, resistance to some of the commercial anti-Giardia drugs has been reported in addition to their harmful side effects. Therefore, novel treatments for giardiasis are required. In this study, we aimed to assess the in vitro activity of crude extracts of Ageratum conyzoides against G. duodenalis trophozoites. METHODS:Plants were classified into three groups based on their flower colors: white (W), purple (P), and white-purple (W-P). Plants were separately cut into leaf (L) and flower (F) parts. Changes in internal organelle morphology of trophozoites following exposure to crude extracts were assessed using transmission electron microscopy (TEM). In subsequent experiments, efficacy of the most active essential oils from crude extracts [half maximal inhibitory concentrations (IC50)???100??g/mL] against G. duodenalis trophozoites was tested. In vitro anti-Giardia assays using essential oils were performed in the same way as those performed using crude extracts. RESULTS:LW-P and FP extracts showed high activity (IC50???100??g/mL) against G. duodenalis trophozoites, with IC50 ±?SD values of 45.67?±?0.51 and 96.00?±?0.46??g/mL, respectively. In subsequent experiments, IC50 ±?SD values of LW-P and FP essential oils were 35.00?±?0.50 and 89.33?±?0.41??g/mL, respectively. TEM revealed the degeneration of flagella and ventral discs of G. duodenalis trophozoites following exposure to crude extracts. CONCLUSION:Crude LW-P and FP extracts of A. conyzoides showed the highest activity against G. duodenalis. Exposure to crude extract induced changes in the flagella and ventral discs of G. duodenalis trophozoites, which play important roles in attachment to the surface of mucosal cells. Our results suggest that the tested extracts warrant further research in terms of their efficacy and safety as giardiasis treatment.


PROVIDER: S-EPMC7076862 | BioStudies | 2020-01-01

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7577037 | BioStudies
1000-01-01 | S-EPMC5295624 | BioStudies
2017-01-01 | S-EPMC5810305 | BioStudies
2020-01-01 | S-EPMC7275508 | BioStudies
2016-01-01 | S-EPMC5070761 | BioStudies
2013-01-01 | S-EPMC3747212 | BioStudies
2018-01-01 | S-EPMC6196658 | BioStudies
2015-01-01 | S-EPMC4625791 | BioStudies
2015-01-01 | S-EPMC4607969 | BioStudies
2017-01-01 | S-EPMC5645933 | BioStudies